Vertex Goes All-In on Our Effort to Conquer Cystic Fibrosis
June 6, 2017
Vertex believes in the Science of Possibilities. Possibilities for patients, because we’re All In for CF. For more than two decades, Vertex has been focused on research to bring new medicines to people with cystic fibrosis.
In this morning’s Boston Globe, our CEO Dr. Jeff Leiden said, “Scientific innovation is where you create value…you’ll never see us make a me-too drug.”
Our commitment to patients is unwavering. Now that we’ve been able to bring to market two medicines, that are eligible for approximately 40 percent of the 75,000 people affected by CF, Vertex is laser-focused on developing additional therapies to benefit the remaining patient population that is affected by other mutations.